ArticleJournal of the American Academy of Dermatology2018
Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Article in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.Seminars in immunopathology · 2025Review
- Safety of Hydroxychloroquine: What a Dermatologist Should Know.American journal of clinical dermatology · 2025Review
- Higher Odds of Adverse Cutaneous Reactions in Patients With Dermatomyositis Treated With Hydroxychloroquine Compared With Methotrexate.ACR open rheumatology · 2023Article
- Immunosuppression in Rheumatologic and Auto-immune Disease.Handbook of experimental pharmacology · 2022Article
- Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study.Journal of the American Academy of Dermatology · 2021Article
- Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design.Computers in biology and medicine · 2021Article
- The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review.Annals of translational medicine · 2021Review
- Pruritus in autoimmune connective tissue diseases.Annals of translational medicine · 2021Review
- Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.Journal of the American Academy of Dermatology · 2020Review
- Safety perspectives on presently considered drugs for the treatment of COVID-19.British journal of pharmacology · 2020Review
- Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.Lupus science & medicine · 2020Review
- COVID-19 leading to acute encephalopathy in a patient with heart transplant.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2020Article
- Treatment of cutaneous lupus erythematosus: current approaches and future strategies.Current opinion in rheumatology · 2020Review
- Review
- Effect ofFrontiers in immunology · 2019Article
- Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?Annals of translational medicine · 2018Review
- Current Treatment for Myositis.Current treatment options in rheumatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAlthough existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remains debated.
objectiveWe investigated the toxicity risk associated with antimalarials in patients with cutaneous lupus erythematosus and dermatomyositis.
methodsA total of 532 patients (mean age, 52.29 years; sample composition by sex, 85.15% female vs 14.85% male) were selected from 2 databases on cutaneous lupus erythematosus (69.92%) and dermatomyositis (30.08%). Details regarding treatment and toxicities were extracted and 5 treatment courses were defined (ie, hydroxychloroquine [HCQ], chloroquine [CQ], quinacrine [Q], HCQ-Q combination therapy [HCQ-Q], and CQ-Q combination therapy [CQ-Q]). The hazard ratio for each major toxicity was estimated by using the Cox proportional hazard model to compare the different treatments with HCQ.
resultsThe most common toxicities included cutaneous eruption, gastrointestinal upset, mucocutaneous dyspigmentation, neurologic toxicity, and retinopathy. The hazards of cutaneous eruption, gastrointestinal upset, and neurologic toxicities were lower with HCQ-Q than with HCQ; however, this may represent selection bias. Although there was increased retinopathy risk with CQ and CQ-Q versus with HCQ, retinopathy was not seen with Q. LIMITATIONS: Retrospective analysis.
conclusionsWith the exception of retinopathy, which was not seen with Q, the risks for other toxicities associated with Q monotherapy or combination treatment were not significantly different from those with HCQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.